HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug ...
Z-endoxifen has demonstrated efficacy in phase 1 and 2 trials, improving progression-free survival and tumor response in ...
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA) Registrational TACTI-004 (KEYNOTE-F91) Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback